BNP Paribas Asset Management
CPRX

BNP Paribas Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

BNP Paribas Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.4K Sell
1,955
-633
-24% -$18.7K ﹤0.01% 1697
2026
Q1 		$64.1K Buy
2,588
+832
+47% +$19.8K ﹤0.01% 1662
2025
Q4 		$41K Buy
1,756
+468
+36% +$10.4K ﹤0.01% 1721
2025
Q3 		$25K Buy
1,288
+35
+3% +$720 ﹤0.01% 1296
2025
Q2 		$27K Buy
+1,253
New +$29.6K ﹤0.01% 1382

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Asset Management's CPRX Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Catalyst Pharmaceutical (CPRX) stake by 24% in Q2 2026, selling an estimated $18.7K and leaving 1,955 shares worth $61.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1697.

BNP Paribas Asset Management first reported a position in CPRX in Q2 2025 and has held it in 5 quarters since. The position peaked at $64.1K in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • BNP Paribas Asset Management held 1,955 shares of Catalyst Pharmaceutical worth $61.4K as of Q2 2026.
  • BNP Paribas Asset Management sold 633 Catalyst Pharmaceutical shares in Q2 2026, an estimated $18.7K.
  • Catalyst Pharmaceutical made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1697 holding.
  • BNP Paribas Asset Management first reported a position in Catalyst Pharmaceutical in Q2 2025 and has held it in 5 quarters since.
  • BNP Paribas Asset Management's Catalyst Pharmaceutical position peaked at $64.1K in Q1 2026.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.